Back to News
Market Impact: 0.2
Adlai Nortye Receives FDA Clearance For AN4035 Phase I Trial
Source: Nasdaq
Healthcare & BiotechProduct Launches
Adlai Nortye Group dosed the first patient in Australia in its global Phase I trial of AN4035. The investigational first-in-class antibody-drug conjugate targets CEACAM5 and delivers a pan-RAS(ON) inhibitor payload, marking an early clinical-development milestone with limited near-term financial visibility.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ANL0.65
More News
- Apple's $2000+ iPhone, Oil Gain Stokes Inflation Fear | Bloomberg Businessweek Daily 9/8/2026
- Stock Movers: Chime, Stryker, Compass Pathways (Podcast)
- Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026
- Pharma major plummets over 10% after third trial disappointment in a week
- Kaplan Fox Continues to Alert Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to a Class Action Deadline on November 2, 2026
- Qualcomm partners with Amazon in data center infrastructure deal